ABIVAX SA-ADR (ABVX)
US00370M1036 - ADR
ABIVAX SA-ADR
NASDAQ:ABVX (5/15/2024, 3:30:00 PM)
13.95
+0.1 (+0.72%)
Company Profile
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 26 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Company Info
ABIVAX SA-ADR
7-11 Boulevard Haussmann
Paris ILE-DE-FRANCE
P: 33153830963
Employees: 26
Website: https://www.abivax.com/
ABVX News
7 months ago - Seeking AlphaFrench biotech Abivax stock tumbles 24% following $217M US IPO (NASDAQ:ABVX)French biotech Abivax's (ABVX) shares dropped 24% after its $217M US IPO. Read more here.
The French biotech company said it has clearance to begin a 1,000 patient trial of its experimental anti-inflammatory drug ABX464 in Covid-19 patients.
ABVX Twits
Here you can normally see the latest stock twits on ABVX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
